BioMimetic Therapeutics, Inc. Receives Filing Letter from FDA for Augment(TM) Bone Graft PMA

Published: Jun 28, 2010

FRANKLIN, Tenn.--(BUSINESS WIRE)--BioMimetic Therapeutics, Inc. (NASDAQ: BMTI) today announced the Food & Drug Administration (FDA) has accepted for review its Premarket Approval (PMA) application for Augmentâ„¢ Bone Graft for use in foot and ankle fusions in the U.S. The FDA has now filed the application and begun the comprehensive review of the clinical module.

Back to news